ZA200601927B - Yeast cell wall for the treatment or prevention of hyperglycemia or for the stabilisation of giycemia - Google Patents
Yeast cell wall for the treatment or prevention of hyperglycemia or for the stabilisation of giycemia Download PDFInfo
- Publication number
- ZA200601927B ZA200601927B ZA200601927A ZA200601927A ZA200601927B ZA 200601927 B ZA200601927 B ZA 200601927B ZA 200601927 A ZA200601927 A ZA 200601927A ZA 200601927 A ZA200601927 A ZA 200601927A ZA 200601927 B ZA200601927 B ZA 200601927B
- Authority
- ZA
- South Africa
- Prior art keywords
- yeast cell
- mass
- cell walls
- hyperglycemia
- dry matter
- Prior art date
Links
- 210000005253 yeast cell Anatomy 0.000 title claims description 59
- 201000001421 hyperglycemia Diseases 0.000 title claims description 42
- 230000002265 prevention Effects 0.000 title claims description 18
- 230000006641 stabilisation Effects 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 claims description 39
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 25
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 24
- 229920002527 Glycogen Polymers 0.000 claims description 19
- 229940096919 glycogen Drugs 0.000 claims description 19
- 229920000057 Mannan Polymers 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 238000011105 stabilization Methods 0.000 claims description 17
- 229920001503 Glucan Polymers 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 210000002421 cell wall Anatomy 0.000 claims description 6
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000008103 glucose Substances 0.000 description 12
- 208000035404 Autolysis Diseases 0.000 description 7
- 206010057248 Cell death Diseases 0.000 description 7
- 230000028043 self proteolysis Effects 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 5
- 229940041290 mannose Drugs 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 238000007824 enzymatic assay Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 102100024023 Histone PARylation factor 1 Human genes 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 108010005335 mannoproteins Proteins 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
YEAST CELL WALLS FOR THE TREATMENT OR PREVENTION OF
HYPESRGLYCEMIA OR FOR THE STABILIZA TION OF GLYCEMIA
The present invention relates to the treatment and the prevention of the hyperglycemia, and the stabilization of awlycemia.
A large number of compounds have already been proposed for the prevention of hyperglycemza, for the treatment of hyperglycemia and/or for the stabilization of glycemia, in particular in the casee of diabetes.
Products based on yeast, such as in particular yeast as sucha, yeast extract, a chromium-bassed glucose tolerance factor (GTF) extracted from a chr-omium-enriched yeast, and also a cellular preparation off brewer’s yeast, have thus: been proposed.
Thus, JP-A-61-167622 proposes an agent for combating dialoetes based on a cellular fract_ ion of brewer’s yeast call ed cell wall in this document and obtained by hydr-olysis of debittered brewer’ss yeast for at least 2 hosurs at a temperature of 50 to 70°C and aqueous extr-action of the water-soluble constituents. Said cell ular fraction of brewer’s yeas t has in particular a gluc=an content of about 14.8%, a mannan content of abowt 13.9%. Said cellular fraction also has a glycogen cont.ent of about 24.9%. Glycogen or liver starch (in
German: “Leberstdrke”) is a storage polysaccharide also pres.ent in the muscles and in par—ticular in the liver.
This. glycogen is also a storage substance in yeast, used by the latter as energy sour-ce for its survival.
Whil e it is one of the main compoments of the cellular fraction described in this Japamese application, it does. not form part of the cell walZl in yeasts.
Accoexding to the present inventi on, it has been now been. observed that it is possible to obtain yeast cell walls that are effective as agent for the prevention and treatment of hyperglycemia and having a low glycogen content, it being posssible for said yeast cell walls to be obtained by a simpole autolysis or enzymatic 55 hydrolysis process.
The term “yeast cell wall” refers to the insoluble fraction of the non-chromium-esnriched yeast cells which is obtained after autolysis or enzymatic hydrolysis, 1Q mainly by proteases, leading to the solubilization of at least 50%, and preferably of at least 60% by mass of the dry matter content of the whole yeast cells and preserving the structural polysaccharides of the cell wall, that is to say the R-—glucans and the mannans, 1% these mannans being in the form of mannoproteins.
This autolysis or enzymatic haydrolysis is performed so as to solubilize most of the storage sugars of the yeast cell such as glycogen and trehalose. The yeast cell walls are obtained by separating the fraction solubilized by autolysis or enzymatic hydrolysis, the latter having a duration pr eferably of at least 18 hours. The preferred processes for autolysis of cream yeasts are described on pages 370 to 377 in the 2% reference manual “Yeast Technology”, 2nd edition, 1991,
G. Reed and T.W. Nogodawitlaana, published by Van
Nostrand Reinhold, New York, ISBN 0-442-31892-~8. The yeast cell walls thus obtained are then typically dried by a conventional drying process, such as spray-drying or drying on rotary drums.
The yeast cell walls according to the invention are cell walls of yeasts of the genus Saccharomyces preferably belonging to thie species Saccharomyces 3% cerevisiae.
Said yeasts are preferably baker’s yeasts. Baker's yeast is a yeast belonging to the species Saccharomyces cerevisiae, manufactured maimly with the aid of an aerobic multiplication or culture as taught in the reference manual “Yeast Technology” cited above and which has not served, before its autolysis or enzymatic hydrolysis, for any purpose, unlike, for example, brewer's yeast which is a by-product of beer manufacture and which has therefore served for “the manufacture of beer before its recovery for dts autolysis or enzymatic hydrolysis. This brewer's yeast was mainly multiplied under anaerobic conditions (the manufacture of beer being an anaerobic process).
The yeast cell walls according to the invention have a total cell wall glucan and mannan content (systematically expressed as equivalent mass of glyc-ose and mannose respectively - see methods of measurem ent below) of at least 34.0% by mass on a dry matter bas is, and a glycogen content (systematically expressed as equivalent mass of glucose - see methods of measurement below) of less than 10.0% by mass on a dry mat ter basis.
Preferably, the yeast «cell walls according to the invention have a total glucan and mannan content of at least 40.0% by mass on a dry matter basis, preferably still of at least 45.0% by mass on a dry matter basis.
The yeast cell walls according to the invention also preferably have a glycogen content of less than 8.0% by mass on a dry matter basis, preferably still of ll. ess than 5.0% by mass on a dry matter basis and more preferably still of less than 3.0% by mass on a dry matter basis.
Usefully, the yeast cell walls according to the invention have an N x 6.25 protein content of 17.0 to 35.0% by mass on a dry matter basis, preferably of 1.8.0 to 26.0% by mass on a dry matter basis.
Advantageously, the yeast cell walls according to the invention have a dry matter content of at least 9 0% by mass, preferably of at least 94% by mass and prefe rably still of at least 96% by mass.
In gen eral, the total glucan and mannan content o f the yeast «ell wall according to the invention is less than or equal to 70% by mass on a dry matter basis. It may in par-ticular be less than or equal to 65% by mass on a dry matter basis. It may also be less than or equ al to 55% by mass on a dry matter basis.
According to one variant of the invention, in ord er to completely or practically completely remove glycogen . from the yeast cell wall, yeast cell walls accordi ng to the invention, obtained as described above, are suspencled in an aqueous suspension, heated in an alkalime medium at between 70°C and 100°C for a ma ximum of three hours, and the fraction solubilized by this treatment is removed, the remaining non-solubi lized fraction being recovered and generally dried. For example, a suspension containing about 12% of yeast cell wall dry matter content in a sodium-conta ining alkalime aqueous medium may be heated at 85°C fox two } hours. The solubilized fraction containing all. the glycogen, but also a large portion of, or everh the entire content of, mannoproteins is removed by centrifugation and washing.
Such a treatment makes it possible to produce yeast cell walls according to the invention having a total ‘ glucan and mannan content of 55% to 70% by mass on a dry ma tter basis, preferably of 60% to 70% by mas s and preferably still of 60 to 65% by mass on a dry matter basis. Such a treatment makes it possible in parti cular to prepare yeast cell walls which contain less than 1.0% k»y mass of glycogen on a dry matter basis, and preferably less than 0.1% by mass of glycogen on a dry matter basis. These yeast cell walls may not coentain mannans.
These yeast cell walls containing a high total glucan and mannan content correspond to one eruwbodiment of an agent according to the invention for the treatment or prevention of hyperglycemia or for the stabilization of glycemia.
They are appropriate for the preparations according to the invention for the treatment or prevention of hypexglycemia or for the stabilizatiom of glycemia.
They may, according to the invention, be used in the preparation of a therapeutic composition for the treatment or prevention of hyperglycemia or for the stabilization of glycemia.
Method for measuring the glycogen content 0.5 ml of 0.25 M Na,CO; is added to a sample of 20 mg of dry yeast cell walls, that is to say having a dry matter content of at least 90% by rnass, and this mixture is kept at 95°C for 4 hours.
The mixture is then brought to a pH off 5.2 by adding 0.3 ml of 1 M acetic acid and 1.2 ml of 0.2 M sodium acetate and by mixing the ingredients. Distilled water is added to obtain a total volume of 2 m1. 0.5 ml of the suspension thus obtained is incubated for 15 hours in the presence of an excess of Aspergillus niger amyloglucosidase, as marketed ly the company
Roch e under the number Cat. No. 102 857, at 55°C.
After centrifugation, the glucose relea sed is measured out ky enzymatic assay.
The enzymatic assay of glucose is described in part icular in the manual “Methods of Biochemical
Anal ysis and Food Analysis - using Single Reagents”, publ ished by Boehringer Mannheim GmbH Biochenica,
© 1988, pa ges 50 to 55, and is preferably carried out using the “Test-Combination D-Glucose/-Fructose”, Cat.
No. 139 10 6 from the subsidiary of the company Roeche :
Boehringer Mannheim GmbH/R-Biopharm GmbH at Darms tadt,
Germany.
The quantity (in mg) of glucose thus as sayed correspondss to the quantity of glycogen present im the sample expmxessed as equivalent mass of glucose.
Method for measuring the total content of glucans and mannans
A sample of 20 mg of dry yeast cell walls, that Ds to say having a dry matter content of at least 90% by mass, is swibjected to acid hydrolysis by mixing it with ml of 2 N HCl, and the mixture is kept in a c losed screw-top DJottle for 4 hours at 103°C in an incu bator with stirring every 15 min. 20
Next, the acidic solution thus obtained is neutra lized and the quantity of glucose and of man nose, respectively, in the neutralized solution is then assayed by the enzymatic route. }
This enzymatic assay of glucose and mannose is also described «on pages 50 to 55 of the manual cited above and is poreferably carried out using the ™ Test-
Combinatiom” Cat. No. 139 106.
The difference is calculated between, on the one hand, the quanti#ty of glucose (expressed in mg) ~as sayed according to this method and the quantity of gl ucose (also expr-essed in mg) assayed for these yeast cell walls by tke method for the measurement of the glycogen content above.
This diffe rence (in mg) between the two quantitiess of glucose as sayed corresponds to the total quantity of glucans present in the sample, this quantity being expresssed as equivalent mass of glucose.
The quantity (in mg) of mannose assayed corresponds to the total quantity of mannans present in the sample, this quantity being expressed as equi valent mass of mannose.
The present invention relates, in the first instance, : 10 to an agent for the treatment of hyperglycemia consisting of yeast cell walls as defimed above, that is to say the yeast cell walls according to the invention. The treatment of hyperglycemia involves . mainly the reduction of glycemia, that is to say of the : blood glucose level.
This a gent according to the invention may be useful in several cases of hyperglycemia, such as in particular the ca ses listed below: (a) for the treatment of hyperglycemia in the case of t ype 2 diabetes (type 2 diabetes being called h ereinafter “condition (a)”); (b) for the treatment of hyperglycemia in the case of . gestational or pregnancy diabetes (gestational or
Pregnancy diabetes being called hereinafter “ condition (b)”); (c) for the treatment of hyperglycemia in the case of prrediabetes (prediabetes being cal led hereinafter “condition (c}”); (d) f£or the treatment of post-prandial hyperglycemia ( the post-prandial state being called hereinafter “condition (d)”).
The present invention also relates to an agent for the prevention of hyperglycemia, said agent consisting of yeast cell walls according to the invention. The preveration of hyperglycemia mainly 1 nvolves keeping glycemia at levels below hyperglycemia.
oo we? 33/3 1927 ) " Said agent may be in particular an agent for the prevention of hyperglycemia in the case of at least on e€ of the conditions {a}, (b), (c) or (d) as defined above.
The present invention also relates to an agent for the stabilization of glycemia, said agent consisting o f yeast cell walls according to the invention. Th e - stabilization of glycemia mainly involves keeping glycemia at levels below hyperglycemia and above hypoglycemia.
Said agent may be in particular an agent for the stabilization of gl ycemia in the case of at least on.e of the conditions (a), (b), (c) or (d).
The agent according to the invention, in its variows embodiments, may be administered in various forms oor presentations, alorie or in combination with other ingredients, such as, for example, one or more other therapeutically act ive ingredients and/or one or more excipients.
Thus, the present invention relates to a preparation for the treatment of hyperglycemia which comprises yeast cell walls according to the invention, as defined above. Said preparation comprises, in other words, &an agent according to tthe invention.
Said preparation aczcording to the invention may be in particular a pre=paration for the treatment of hyperglycemia in tthe case of at least one of the conditions (a), (b)e (c) or (d).
The present inventieon also relates to a preparation for the prevention of hyperglycemia which comprises yeast cell walls according to the invention.
Said preparation may be in particular a preparation for
- go - ] the prevention of hyperglycemia in the case of at least one of the conditions (a), (b), (c) or (d).
The present invention also relates to a preparation for the stabilization of glycemia which comprises yeast cell walls according to the invention.
Said preparation may be in particular a preparation for the stabilization of glycemia in the case of at least one of the conditions (a), (b), (c) or (d).
The preparation according to any one of the above embodiments is generally a preparation for administration by the oral route. .
The preparation may be provided in particular in the form of a tablet, a capsule, a pill, a powder, granules or a suspension.
The preparation according to the invention may also comprise one or more therapeutically active agents, and in particular one or more hypoglycemic agents. The preparation may thus comprise one or more vitamins, one or more dietary minerals, amd the like. .
The preparation may also comprise one Or more pharmaceutically acceptable excipients.
The preparation according to the invention may be provided in particular im the form of a dose for ingestion corresponding to a quantity of yeast cell wall dry matter content according to the invention of less than 10 g, preferably from 1 to 8 g, preferably still from 1 to 7 gq.
The present invention also relates to the use, in the preparation of a thera peutic composition or a medicament, of the yeast <ell walls according to the invention, various embodiments of which are defined above.
The invention relates in particular to the use of these yeast cell walls in the production of one of the compositions according to the invention as defined above.
The present invention thus relates to the use of yeast cell walls according to the invention in the 1 0 preparation of a therapeutic <«<omposition for the treatment of hyperglycemia.
The yeast cell walls according to the invention may be used in particular in the preparation of a therapeutic 1.5 composition for the treatment of hyperglycemia in the case of at least one of the conditions (a), (b), (c) or (dy.
The present invention also relates to the use of yeast cell walls according to the invention in the preparation of a therapeutic composition for the prevention of hyperglycemia.
The yeast cell walls according to the invention may be used in particular in the prepara tion of a therapeutic composition for the prevention of hyperglycemia in the case of at least one of the conditions (a), (b), (c) or (d).
The present invention also relate s to the use of yeast cell walls according to the invention in the preparation of a therapeutic composition for the stabilization of glycemia.
The yeast cell walls according to= the invention may be used in particular in the preparation of a therapeutic composition for the stabilizatiom of glycemia in the case of at least one of the condi®ions (a), (b), (c¢) or (d).
11 ng5:01920 eld *
The pharmaceutical composition is as a general rule a composition for administration by the oral route. 5S The pharmaceutical composition rnay be provided in particular in the form of a tablet, a capsule, a pill, a powder, granules or a suspension.
The yeast cell walls according to the invention may be used in particular in the preparation of a pharmaceutical composition also comprising: . one or more therapeutically active agents, in particular one or more hypoglycemic agents, and/or oe one or more vitamins, one or more dietary minerals, and the like.
The pharmaceutical composition may also comprise one or more pharmaceutically acceptable excipients.
The yeast cell walls according to the invention may be used in particular for the prepara tion of a therapeutic composition in the form of a dose for ingestion corresponding to a quantity of yeast cell wall dry matter content according to the irmvention of less than 10 g, preferably from 1 to 8 g, preferably still from 1 to 7 g.
The present invention additionallys relates to a method for the treatment of hyperglycemia in a patient, comprising the administration to the patient of one agent according to the invention for the treatment of hyperglycemia or of a preparation according to the invention for the treatment of hyp erglycemia.
The method for the treatment of hyperglycemia may be in particular a method for the treatment of hyperglycemia in the case of at least one of the conditions (a), (b), (c) or (d).
Claims (28)
1. An agent for use in the treatment or prevention of hyperglycemia, said agent consisting of cell walls of yeast of the genus Saccha romyces cerevisiae, said yeast cell walls having: ° a total glucan and mannan content of at least
34.0% by mass on a dxy matter basis, and » a glycogen content of less than 10.0% by mass on a dry matter basis.
2. The agent according to claim 1, having a total glucan and mannan content of at least 40.0% by mass on a dry matter basis.
3. The agent according to claim 2, having a total glucan and mannan content of at least 45.0% by mass on a dry matter basis.
4. The agent according to any one of claims 1-3, having a glycogen content of less than 8.0% by mass on a dry matter basis.
5. The agent according to claim 4, having a glycogen content of less than 5.0% by mass on a dry matter basis.
6. The agent according to claim 5, having a glycogen content of less than 3.0% by mass on a dry matter basis.
7. The agent according to any one of claims 1-6, in which the yeast cell walls have a total glucan and mannan content of less than or equal to 70% by mass on a dry matter basis.
8. The agent according to any one of claims 1-7 , in AMENDED SHEET which the yeast cell walls have a total glucan and mannan content of 55% to 70% by mass on a dry matter basis.
9. The agent according to claim 8, in which the yeast cell walls have a total glucan and mannan content of 60% to 70% by mass, and preferab ly still of 60% to 65% by mass on a dry matter basis.
10. The agent according to claim 9, in which the yeast cell walls have a total glucan and mannan content of 60% to 65% by mass on a dry matte r basis.
11. The agent according to any one of the preceding claims, in which the yeast cell walls have a glycogen content of less than 1.0% by mass on a dry matter basis.
12. The agent according to c¢l aim 11, in which the yeast cell walls have a glycogern content of less than
0.1% by mass on a dry matter basi s.
13. The agent according to any one of the preceding claims, in which the yeast cell walls have a dry matter content greater than or equal to 90% by mass.
14. The agent according to claim 13, in which the yeast cell walls have a dry matteer content greater than or equal to 94% by mass.
15. The agent according to claim 14, in which the yeast cell walls have a dry matteer content greater than or equal to 96% by mass.
16. The agent according to any one of the preceding claims, characterized in that t=he hyperglycemia is a hyperglycemia in the case of type 2 diabetes. AMENDED SHEET
17. An agent for use in the stabilization of glycemia, the agent consisting of yeast «ell walls as defined in any one of claims 1 to 15.
18. The agent according to claim 17, for the stabilization of glycemia in the case of type 2 diabetes.
19. A preparation for use in the treatment or prevention of hyperglycemia, said preparation comprising yeast cell walls as defined in any one of claims 1 to 15.
20. Preparation according to claim 19, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.
21. A preparation for use in the stabilization of glycemia, preparation comprising yeast cell walls according to any one of claims 1 to 15.
22. The preparation according to claim 21, for the stabilization of glycemia ima the case of type 2 diabetes.
23. The use of yeast cell walls according to any one of claims 1 to 15, in the preparation of a therapeutic composition for the treatment or prevention of hyperglycemia.
24. The use according to claim 23, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.
25. The use of yeast cell walls according to any one of claims 1 to 15, in the preparation of a therapeutic composition for the stabilization of glycemia. AMENDED SHEET
26. The use according to claim 25, for- the preparation of a therapeutic composition for the stabilization of glycemia in the case of type 2 diabetes .
27. Yeast cell walls for the treatment of hyperglycemia substantially as herein described with reference to and as exemplified in Example A.
28. Use of yeast cell walls in the ira the preparation 1Q of a therapeutic composition for tlhe treatment or prevention of hyperglycemia as hereim described with reference to and as exemplified in Exampole B. AMENDED SHEET
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03018222 | 2003-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601927B true ZA200601927B (en) | 2007-05-30 |
Family
ID=34923808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601927A ZA200601927B (en) | 2003-08-11 | 2006-03-07 | Yeast cell wall for the treatment or prevention of hyperglycemia or for the stabilisation of giycemia |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN100377719C (en) |
| UA (1) | UA85561C2 (en) |
| ZA (1) | ZA200601927B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2919187B1 (en) * | 2007-07-25 | 2009-11-27 | Lesaffre & Cie | USE OF YEAST SKIN FOR THE TREATMENT AND / OR PREVENTION OF HYPERINSULINEMIA. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2825004B1 (en) * | 2001-05-22 | 2005-02-11 | Bio Springer | SAFE DIETETIC PRODUCT |
-
2004
- 2004-08-10 CN CNB2004800229975A patent/CN100377719C/en not_active Expired - Fee Related
- 2004-08-10 UA UAA200602623A patent/UA85561C2/en unknown
-
2006
- 2006-03-07 ZA ZA200601927A patent/ZA200601927B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1835761A (en) | 2006-09-20 |
| CN100377719C (en) | 2008-04-02 |
| UA85561C2 (en) | 2009-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090022758A1 (en) | Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia | |
| KR101593705B1 (en) | Use of yeast flakes for treating and/or preventing hyperinsulinemia | |
| EP2255814B1 (en) | Agent for increasing the quantity of hyaluronic acid | |
| TW200831114A (en) | Activity enhancer for detoxifying enzyme | |
| ZA200601927B (en) | Yeast cell wall for the treatment or prevention of hyperglycemia or for the stabilisation of giycemia | |
| CN106822097A (en) | A kind of pharmaceutical composition containing orlistat for losing weight | |
| JP2005179213A (en) | Liver trouble inhibiting composition and method for producing the same | |
| JP2010095460A (en) | Purine body absorption inhibitor and blood uric acid level reducing agent | |
| US5773426A (en) | Proteoglucan and antidiabetic drug thereof | |
| CN113727724A (en) | Saccharomyces cerevisiae strain for the treatment and/or prevention of oropharyngeal candidiasis | |
| US20240148778A1 (en) | Glycoside inhibitors of yeast | |
| DE102006014420A1 (en) | New 5-D-fructose dehydrogenase in combination with an enzyme, e.g. glucose isomerase, useful for preventing or treating adiposity | |
| CN106563038B (en) | Taurine and fat-soluble tea polyphenol compound composition, preparation method and application thereof | |
| CN106858603A (en) | The New function of chitobiose and its application in health food | |
| KR20130067618A (en) | Extract from salted and fermented shrimp, manufacturing method of the same and composition containing the same | |
| JPH07109223A (en) | Improver for activating liver function | |
| DE102006014424A1 (en) | Use of glucose isomerase in combination with 5-D-fructose dehydrogenase and an enzyme, e.g. invertase, for producing a pharmaceutical composition for preventing, treating, or diagnosing diabetes |